Gene clues may predict blood cancer outcomes

NCT ID NCT02619565

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study enrolled 349 people with myelodysplastic syndromes (MDS) to see how certain gene mutations affect survival. Researchers collected blood samples at diagnosis and tracked patients over time. The goal was to understand which mutations are linked to better or worse outcomes, which could help guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better predict disease progression and tailor treatments for people with myelodysplastic syndromes.

What could go wrong

This is an observational study, not a treatment trial. It only looks at genetic patterns and does not test any new therapy, so it cannot directly improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative neoplasm therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Assistance publique-Hôpitaux de Paris, Hôpital Cochin

    Paris, 75014, France